BETHESDA, Md., Feb. 6, 2014 /PRNewswire/ -- Northwest
Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a
biotechnology company developing DCVax® personalized immune
therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO
CEO and Investor Conference 2014, which is being held in
New York on February 10-11, 2014.
NW Bio's presentation will take place on Monday, February 10, at 11:30 a.m. EST in the Basildon Room at the
Waldorf-Astoria in New York
City. There will be a live audio webcast of the presentation
available at http://nwbio.com/webcasts/. During her
presentation, Ms. Powers will provide an overview of the Company's
cancer vaccine platform technology, product pipeline and clinical
programs with DCVax-L and DCVax-Direct.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both
the United States and
Europe. The Company has a broad platform technology for DCVax
dendritic cell-based vaccines. The Company's lead program is
a 312-patient Phase III trial in newly diagnosed Glioblastoma
multiforme (GBM). GBM is the most aggressive and lethal form
of brain cancer. The Company is also under way with a
60-patient Phase I/II trial with DCVax-Direct for all inoperable
solid tumors cancers, with a primary efficacy endpoint of tumor
regression. The Company also previously received clearance
from the FDA for a 612-patient Phase III trial in prostate
cancer. The Company also conducted a Phase I/II trial with
DCVax for metastatic ovarian cancer together with the University of
Pennsylvania.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "design," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. Actual results may differ
materially from those projected in any forward-looking
statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from
those anticipated, such as risks related to the Company's and
Cognate's abilities to carry out the intended expansions
contemplated in the Cognate Agreements, risks related to the
Company's ability to enroll patients in its clinical trials and
complete the trials on a timely basis, the uncertainty of the
clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company's products will
demonstrate safety and efficacy, and risks related to the Company's
ability to raise additional capital. Additional information
on these and other factors, including Risk Factors, which could
affect the Company's results, is included in its Securities and
Exchange Commission ("SEC") filings. Finally, there may be
other factors not mentioned above or included in the Company's SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement. You should
not place undue reliance on any forward-looking statements.
The Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics